RESUMO
2-(2',4'-Dibromophenoxy)-4,6-dibromophenol isolated from the marine sponge Dysidea granulosa (Bergquist) collected off the coast of Lakshadweep islands, Indian Ocean, exhibited potent and broad spectrum in-vitro antibacterial activity, especially against methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive Staphylococcus aureus (MSSA), vancomycin resistant Enterococci (VRE), vancomycin sensitive Enterococci (VSE) and Bacillus spp. Minimal inhibitory concentration (MIC) was evaluated against 57 clinical and standard strains of Gram positive and Gram negative bacteria. The observed MIC range was 0.117-2.5 microg/mL against all the Gram positive bacteria and 0.5-2 microg/mL against Gram negative bacteria. The in-vitro antibacterial activity observed was better than that of the standard antibiotic linezolid, a marketed anti-MRSA drug. The results establish 2-(2',4'-dibromophenoxy)-4,6-dibromophenol, as a potential lead molecule for anti-MRSA and anti-VRE drug development.
Assuntos
Antibacterianos/farmacologia , Dysidea/química , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Éteres Fenílicos/farmacologia , Animais , Antibacterianos/administração & dosagem , Antibacterianos/isolamento & purificação , Enterococcus/efeitos dos fármacos , Oceano Índico , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Testes de Sensibilidade Microbiana , Éteres Fenílicos/administração & dosagem , Éteres Fenílicos/isolamento & purificação , Resistência a VancomicinaRESUMO
A novel dimeric azine derivative designated as limnazine (1) has been isolated from the culture broth of an aquatic Bacillus sp. strain GW90a. The structure has been elucidated, on the basis of spectral data, as N,N'-bis(2,2,6-trimethylchroman-4-ylidene)azine and was additionally confirmed by synthesis. Limnazine (1) is inactive against algae, fungi, and bacteria.